Synthesis and SAR of highly potent dual 5-HT1A and 5-HT 1B antagonists as potential antidepressant drugs

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 24, 2005, Pages 5567-5573

  Kling, Andreas ^a   Lange, Udo E W ^a   Mack, Helmut ^a   Bakker, Margot H M ^a   Drescher, Karla U ^a   Hornberger, Wilfried ^a   Hutchins, Charles W ^b   Möller, Achim ^a   Müller, Reinhold ^a   Schmidt, Martin ^a   Unger, Liliane ^a   Wicke, Karsten ^a   Schellhaas, Kurt ^c   Steiner, Gerd ^c  

^a ABBOTT GMBH AND CO KG   (Germany)

^b ABBOTT LABORATORIES   (United States)

^c BASF SE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ISOQUINOLINE DERIVATIVE; N 4 ARYLPIPERAZINYL N' ETHYL 5,6,7,8 TETRAHYDROPYRIDO[4', 3':4,5]THIENO[2,3]PYRIMIDIN 4(3H) ONE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SEROTONIN; SEROTONIN 1A ANTAGONIST; SEROTONIN 1B ANTAGONIST; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; EMBRYO; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; RAT; SEROTONIN RELEASE; STRUCTURE ACTIVITY RELATION;

ANTIDEPRESSIVE AGENTS; HUMANS; INDOLES; KINETICS; MODELS, MOLECULAR; PIPERAZINES; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT1B; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA;

EID: 27644480407     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.04.077     Document Type: Article

References (49)

1. A. Doris, K. Ebmeier, and P. Shajahan Lancet 354 1999 1369
2. R.M. Hirschfeld, S.A. Montgomery, M.B. Keller, S. Kasper, A.F. Schatzberg, H.J. Moller, D. Healy, D. Baldwin, M. Humble, M. Versiani, R. Montenegro, and M. Bourgeois J. Clin. Psychiatry 61 2000 268
3. C. Holden Science 288 2000 39
4. A. Pelissolo, and J.-P. Lepine S.A. Montgomery J.A. den Boer Perspectives in Psychiatry Vol. 8, Epidemiology of Depression and Anxiety Disorder 2nd ed. 2001 Wiley & Sons Chichester, UK
5. D.A. Slattery, A.L. Hudson, and D.J. Nutt Fundam. Clin. Pharm. 18 2004 1
6. E.J. Nestler, M. Barrot, R.J. Dileone, A.J. Eisch, S.J. Gold, and L.M. Monteggia Neuron 34 2002 13
7. M.K. Sun, and D.L. Alkon Curr. Drug Targets 1 2002 575
8. J. Vetulani, and I. Nalepa Eur. J. Pharmacol. 405 2000 351
9. V. Snow, S. Lascher, and C. Mottur-Pilson Ann. Intern. Med. 132 2000 738
10. J.W. Williams, C.D. Mulrow, E. Chiquette, P. Noel, C. Aguilar, and J. Cornell Ann. Intern. Med. 132 2000 743
11. D. Nutt Eur. Neuropsychopharmacol. 10 Suppl. 4 2000 S433
12. D. Spinks, and G. Spinks Curr. Med. Chem. 9 2002 799
13. S. Peretti, R. Judge, and I. Hindmarch Acta. Psychiatr. Scand. 403 2000 17 Supplementum
14. L. Lanfumey, and M. Hamon Curr. Drug Targets-CNS Neurol. Disord. 3 2004 1
15. D.N. Middlemiss, G.W. Price, and J.M. Watson Curr. Opin. Pharmacol. 2 2002 18
16. J.A. Stamford, C. Davidson, D.P. McLaughlin, and S.E. Hopwood Trends Neurosci. 23 2000 459
17. R. Martin-Ruiz, and L. Ugedo Neuropharmacology 41 2001 72
18. I.A. Pullar, J.R. Boot, R.J. Broadmore, T.A. Eyre, J. Cooper, G.J. Dsanger, S. Wedley, and S.N. Mitchell Eur. J. Pharm. 493 2004 85
19. C. Moret, and M. Briley Neuropharmacology 36 1997 1713
20. H.J. Bidmon, A. Schleicher, K. Wicke, G. Gross, and K. Zilles Naunyn-Schmiedeberg's Arch. Pharmacol. 363 2001 364
21. N.B. Barnes, and T. Sharp Neuropharmacology 38 1999 1083
22. J.F. Heiser, and C.S. Wilcox CNS Drugs 10 1998 343
23. M. Barros, E.L. Mello Jr., R.S. Maior, c.P. Müller, M.A. de Souza Silva, R.J. Carey, J.P. Huston, and C. Tomaz Eur. J. Pharm. 482 2003 197
24. B.J. Cao, and R.J. Rodgers Neurosci. Biobehav. Rev. 23 1998 247
25. F. Artigas, L. Romero, C. de Montigny, and C. Blier Trends Neurosci. 19 1996 378
26. E.A. Rabiner, R.N. Gunn, M.E. Castro, P.A. Sargent, P.J. Cowen, M.J. Koepp, J.H. Meyer, C.J. Bench, P.J. Harrison, A. Pazos, T. Sharp, and P.M. Grasby Neuropsychopharmcology 23 2000 285
27. R.E. Mewshaw, D. Zhou, P. Zhou, X. Shi, G. Hornby, T. Spangler, R. Scerni, D. Smith, L.E. Schechter, and T.H. Andree J. Med. Chem. 47 2004 3823
28. C. Moret, and M. Briley Eur. J. Pharmacol. 404 2000 1
29. C. Ahlgren, A. Eriksson, P. Tellefors, S.B. Ross, C. Stenfors, and A. Malmberg Eur. J. Pharmacol. 499 2004 67
30. C. Stenfors, T. Hallerbäck, G. Larsson, C. Wallsten, and S.B. Ross Naunyn-Schmiedeberg's Arch. Pharmacol. 369 2004 330
31. AstraZeneca development pipeline: NCEs and line extensions; AstraZeneca plc Company World Wide Web site October 06, 2004.
32. C. Roberts, G.W. Price, and B.J. Jones Eur. J. Pharmacol. 326 1997 23
33. C. Stenfors, T. Magnusson, L.G. Larsson, H. Yu, M. Hallbus, O. Magnusson, and S.B. Ross Naunyn-Schmiedeberg's Arch. Pharmacol. 359 1999 110
34. J. Watson, C. Roberts, C. Scott, I. Kendall, L. Collin, N.C. Day, M.H. Harries, E. Soffin, C.H. Davies, A.D. Randall, T. Heightman, L. Gaster, P. Wyman, C. Parker, G.W. Price, and D.N. Middlemiss Br. J. Pharmacol. 133 2001 797
35. C. Roberts, G.W. Price, and D.N. Middlemiss Brain Res. Bull. 56 2001 463
36. Methods and modeling software according to: C.W. Hutchins Endocrin. J. 2 1994 7
37. 1A.
38. B.B. Yao, C.W. Hutchins, T.L. Carr, S. Cassar, J.N. Masters, Y.L. Bennani, T.A. Esbenshade, and A.A. Hancock Neuropharmacology 44 2003 773
39. T.W. von Geldern, C.W. Hutchins, J.A. Kester, J.R. Wu-Wong, W. Chiou, D.B. Dixon, and T.J. Opgenorth J. Med. Chem. 39 1996 957
40. The model discussed here is in contradiction to a functional model suggested by other authors L.M. Gaster, F.E. Blaney, S. Davies, D.M. Duckworth, P. Ham, S. Jenkins, A.J. Jennings, G.F. Joiner, F.D. King, and K.R. Mulholland J. Med. Chem. 41 1998 1218
41. B.B. Hoffmann, and R.J. Lefkowitz A.G. Gilmann T.W. Rall A.S. Nies P. Taylor 8th ed. The Pharmacological Basis of Therapeutics 1990 Pergamon Press New York, USA
42. Detailed synthetic protocols in: Steiner, G.; Schellhass, K.; Lubisch, W.; Holzenkamp, U.; Starck, D.; Knopp, M.; Szabo, L.; Emling, F.; Garcia-Ladona, F. X.; Hofmann, H. P.; Unger, L. DE 19900545, 2000; Chem. Abstr. 2000, 133, 89541.
43. R.W. Sabnis, D.W. Rangnekar, and N.D. Sonawane J. Heterocycl. Chem. 36 1999 333
44. J.P. Wolfe, S. Wagaw, and S.L. Buchwald J. Am. Chem. Soc. 118 1996 7215
45. Joiner, G. F.; Gaster, L. M. WO 9511243, 1995; Chem. Abstr. 1995, 123, 198831.
46. J. Martinez-Esparza, A.M. Oficialdegui, S. Perez-Silanes, H. Begona, L. Orus, J.A. Palop, B. Lasheras, J. Roca, M. Mourelle, A. Bosch, J.C. Del-Castillo, R. Tordela, J. Del Rio, and A. Monge J. Med. Chem. 44 2001 418
47. Assay setup and screening procedures: Bakker, H. M.; Hornberger, W.; Kling, A.; Lange, U. E. W.; Mack, H.; Moeller, A., Schellhaas, L.; Schmidt, M.; Steiner, G. ; Wicke, K. WO 2004055024, 2004; Chem. Abstr. 2004, 141, 89095.
48. max < 20%).
49. J.F. Cryan, A. Markou, and I. Lucki Trends Pharmacol. Sci. 23 2002 238